The ICRU Reference Point
As a general principle, the present system of recommendations for reporting doses is based on the selection of a point within the PTV, which is referred to as the ICRU Reference Point.
The ICRU Reference Point shall be selected according to the following general criteria:
(1) the dose at the point should be clinically relevant;
(2) the point should be easy to define in a clear and unambiguous way;
(3) the point should be selected so that the dose can be accurately determined; (4) the point should be in a region where there is no steep dose gradient. These recommendations will be fulfilled if the ICRU Reference Point is located: -always at the center (or in a central part) of the PTV, and -when possible, at the intersection of the beam axes.
The dose at the ICRU Reference Point is the ICRU Reference Dose and shall always be reported.
The Dose Variation Throughout the CTV
Tumor control depends on the dose to the CTV and its variation. However, the variation in CTV dose can only be estimated from the variation in the PTV dose.
A certain degree of inhomogeneity of the absorbed dose throughout the PTV is always present. A dose variation may even be desirable in some instances.
According to the recommendations already published (lCRU Report 50, ICRU [1993] ), as a basic requirement, the following doses shall be reported:
• the dose at the ICRU Reference Point, • the maximum dose to the PTV, • the minimum dose to the PTV The PTV and the PRV are fixed volumes related to fixed anatomical structures, and thus allow for an accurate computation of the dose at the center, the maximum dose, and the minimum dose and for the presentation of dose-volume histograms. Such histograms should be reported for the PTV and PRV, when available.
Since the CTV can move in space and can change size and shape, the dose at the center, the maximum and the minimum dose, and the dose-volume histograms cannot be determined with high accuracy. As far as the dose at the center ofthe CTV is concerned, its value is generally close to that of the dose at the center of the PTV, which thus can be reported as a reasonable estimate of the dose at the center of the CTV As far as the maximum dose to the CTV is concerned, its value is generally close to that of the maximum dose to the PTV, which thus can be reported as a reasonable estimate of the maximum dose to the CTV As far as the minimum dose to the CTV is concerned, it is by definition, equal to or larger than the minimum dose to the PTV The minimum dose to the PTV can thus be considered as a lower limit of the possible range of minimum dose values for the CTV A dose-volume histogram can be computed for the PTV, since this is a fixed volume. Some parts (close to the border) of the PTV could (for presentation in an average section) be outside the body contour. In such situations, dose distributions, such as dose-volume histograms, must be computed only for that part of the PTV completely enclosed by the average body surface (see Fig. 2 .13.). Furthermore, such information for the GTV, CTV, and lTV should, when feasible, be reported.
The Three Levels of Dose Evaluation for Reporting
The level of completeness and accuracy of reporting therapeutic irradiation depends to a large extent on the situation in the department and on the aim of the treatment. Different levels of ambition for dose evaluation can be identified for different clinical situations. Three levels have been selected for reasons given below, but it is recognized that intermediate levels could also be identified.
In the following paragraphs, only the basic, minimal requirements are outlined. However, as a general rule, reporting of any additional available information considered to be clinically relevant is recommended.
Since the publication of ICRU Report 50 in 1993, some experimental techniques have been fully implemented and have become available as commercial software and equipment. Hence, the description of the three levels had to be changed accordingly. This is reflected in the definitions of the three reporting levels in this Report.
Levell.
The requirements should be followed in all centers, for all patients. They constitute the minimum standard below which safe and accurate radiotherapy cannot be performed. At this level, it is assumed that the dose at the ICRU Reference Point can be accurately determined as well as an estimate of the maximum and minimum doses to the PTV, using at least central-axis depth dose tables and standard isodose charts.
These basic level requirements imply that medical and physics expertise as well as appropriate equipment are available (see, e.g., Official Journal of the European Commission, 1997; Aletti and Bey, 1995) .
The standards of dose planning at this level allow the exchange of more complete and relevant information between different centers.
At this level, it is assumed that the GTV, CTV, OR, PTV, and PRV can be defined using reliable patient data acquisition tools and/or modern imaging techniques under reliable conditions (e.g., a series of CT and/or MRI sections). It is also assumed that complete dose distributions are available in planes or volumes, with inhomogeneity corrections, when appropriate.
There must be a full quality assurance program covering the whole procedure.
Level 3.
Level 3 includes the development of new techniques for which reporting criteria are not yet established (e.g., BNCT, intensity modulation, etc.).
Some procedures, which are now at level 3, can become level 2 with the development of techniques, equipment and standards.
At any level, the dose at the ICRU Reference Point and the best estimation of the maximum and the minimum dose to the PTV should be reported.
Organs at Risk (OR)
To be able to calculate the probability oflate effects in normal tissues, one must consider not only dose and fractionation, but also volumes of the Organ at Risk irradiated.
For each Organ at Risk, when part ofthe organ or the whole organ is irradiated above the accepted tolerance level, the maximum dose should be reported as defined in ICRU Report 50, Section 2.4.3 (Levell).
Examples: Maximum spinal cord dose = 42 Gy, 10 cm C1-C4; left kidney dose = 21 Gy, whole kidney.
The volume receiving more than the accepted tolerance dose should be evaluated from the dosevolume histograms (Level 2 and above).
Reporting Doses in a Series of Patients

Introduction
The first part of the present report, as well as ICRU Reports 29 and 50, deal with dose reporting in a single individual patient. A different situation is encountered when reporting the results of treatment in a series of patients. For that purpose, the following rules are recommended.
Reporting Prescription of Treatment (Protocol)
The description of volumes must be consistent with the definitions used in this report (see above).
The prescribed dose to be given to the PTV and its fractionation must also be described as indicated in this report. An example of such a description is given in Table 3 .1 and is also illustrated for the cases in the Appendix. (c) Planning Target Volume Definition by Group. Group 1: PTV is the CTV with a 0.5 to 1.0 cm margin. Group 2: PTV 1 is the CTV 1 with a 0.5 to 1.0 cm margin. PTV z is the CTV 2 with a 0.5 to 1.0 cm margin. Group 3: PTV is the CTV with a 0.5 to 1.0 cm margin.
B. Example of prescription dose to PTV 1 and PTV z (as defined above in A. In clinical practice, it is not always possible to deliver the prescribed dose and dose distribution within the PTV for each patient. When collecting data over a considerable time span, such as in retrospective analyses, great variation in dose and fractionation may be encountered, as exemplified in Figure 3 .1. There may also have been changes in the policy regarding factors such as prescription (e.g., the use of the ICRU Reference Dose rather than (Landberg et al., 1980) . mInImUm dose), and dose normalization. Such changes may significantly influence the doses that were given to the patients, even though such a change may not be easily recognized. Even within a controlled clinical trial, some variations occur (Figure 3.2. ). However, it is important that, for a series of patients, the principles for reporting volumes and doses follow the general recommendations for each individual patient.
Reasons for deviations from the prescribed dose level may arise from interruptions due to deteriorating patient condition, hardware break down, or re-evaluation of the patient resulting in a different prescription (e.g., change from radical to palliative intent). Thus, the final dose variation in a series of patients may be considerable and not lend itself to being reported according to the previously recommended principles.
Hence, that proportion of patients in whom the dose variation is less than :::':::5%, :::':::5-10%, and more than:::'::: 10%, respectively, relative to the prescribed dose at the ICRU Reference Point shall be reported.
This can be illustrated in a simple diagram, as exemplified in Figure 3 .3. The reasons for not delivering the prescribed dose should be clearly stated. Preferably, analysis of important end-points such as survival and local tumor control should be carried out for the entire patient series, as well as for those patients who fulfilled the prescription and for those who did not.
When reporting treatment, e.g., in a scientific journal, it is recommended that the prescribed CTV and PTV and the corresponding doses be illustrated in an isodose distribution chart, giving the total dose inGy.
The reporting of treatment techniques only in terms of field sizes and/or portal boundaries relative to anatomical structures (e.g., 10 cm X 12 cm pelvic field) is not sufficient. 
